<div id="readability-page-1"><p><span>ALT5 Sigma (NASDAQ:ALTS - Get Free Report)</span> was downgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report issued on Saturday.</p><p>Separately, Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of ALT5 Sigma in a report on Monday, December 29th. One analyst  has rated the stock with a Sell rating,  According to MarketBeat, ALT5 Sigma  has a consensus rating of &#34;Sell&#34;.</p><p><b>Read Our Latest Analysis on ALTS</b></p><h2>ALT5 Sigma Trading Up 2.4%</h2><p>NASDAQ ALTS opened at $0.98 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.79 and a quick ratio of 0.79. ALT5 Sigma has a twelve month low of $0.87 and a twelve month high of $10.95. The company's 50-day simple moving average is $1.31 and its 200 day simple moving average is $1.72. </p><p>ALT5 Sigma (NASDAQ:ALTS - Get Free Report) last posted its earnings results on Saturday, April 11th. The company reported ($6.19) earnings per share (EPS) for the quarter. The firm had revenue of $5.37 million during the quarter. ALT5 Sigma had a net margin of 133.06% and a return on equity of 8.60%. </p><h2>Institutional Trading of ALT5 Sigma</h2><p>Several hedge funds have recently modified their holdings of ALTS. Balyasny Asset Management L.P. bought a new stake in shares of  ALT5 Sigma during the fourth quarter valued at approximately $26,000.  Arete Wealth Advisors LLC bought a new stake in shares of  ALT5 Sigma during the third quarter valued at approximately $28,000.  Profund Advisors LLC bought a new stake in shares of  ALT5 Sigma during the third quarter valued at approximately $28,000.  Victory Capital Management Inc. bought a new stake in shares of  ALT5 Sigma during the third quarter valued at approximately $33,000.  Finally, First Citizens Bank &amp; Trust Co. bought a new stake in shares of  ALT5 Sigma during the third quarter valued at approximately $35,000. 6.27% of the stock is owned by institutional investors. </p><h2>About ALT5 Sigma</h2> (Get Free Report)<p>ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than ALT5 Sigma</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ALT5 Sigma Right Now?</h2><p>Before you consider ALT5 Sigma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALT5 Sigma wasn't on the list.</p><p>While ALT5 Sigma currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ALTS

SBIO

AIFC

<p>Wall Street Zen has downgraded ALT5 Sigma (NASDAQ:ALTS) from a "sell" to a "strong sell" rating. The company reported a net margin of 133.06% and a return on equity of 8.60%, with a recent trading price of $0.98. Institutional investors hold 6.27% of the stock, and the company focuses on developing non-opioid therapies for pain and addiction. Despite the downgrade, some analysts suggest other stocks may be better investment options.</p>

ALT5 Sigma (NASDAQ:ALTS) Cut to "Strong Sell" at Wall Street Zen